Page 79 - AN-3-1

Advanced Neurology COVID-19 and neurodegenerative diseases

of these diseases. To develop appropriate interventions 5. Kumar S, Veldhuis A, Malhotra T. Neuropsychiatric and
targeting the link between COVID-19 and these disease, cognitive sequelae of COVID-19. Front Psychol. 2021;12:577529.
it is imperative to conduct long-term, comprehensive doi: 10.3389/fpsyg.2021.577529
investigations involving larger cohorts of people of varying
ages, disease duration, and ethnicity to explore the effects 6. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2
and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154.
of SARS-CoV-2 on neurodegenerative disorders.
doi: 10.1038/s41579-020-00459-7
Acknowledgments 7. Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, et al.
None. COVID-19 infection: An overview on cytokine storm and
related interventions. Virol J. 2022;19(1):92.
Funding doi: 10.1186/S12985-022-01814-1

None. 8. Jarius S, Pache F, Körtvelyessy P, et al. Cerebrospinal fluid
findings in COVID-19: A multicenter study of 150 lumbar
Conflict of interest punctures in 127 patients. J Neuroinflammation. 2022;19(1):19.

The authors declare no conflicts of interest. doi: 10.1186/S12974-021-02339-0
Author contributions 9. Elmakaty I, Ferih K, Karen O, et al. Clinical implications
of COVID-19 presence in CSF: Systematic review of case
Conceptualization: Amaan Javed reports. Cells. 2022;11(20):3212.
Writing – original draft: Anika Batra, Mehak Singh, Parnica doi: 10.3390/Cells11203212
Sarkar
Writing – review & editing: Anika Batra, Mehak Singh, 10. Veleri S. Neurotropism of SARS-CoV-2 and neurological
diseases of the central nervous system in COVID-19
Parnica Sarkar
patients. Exp Brain Res. 2022;240(1):9-25.
Ethics approval and consent to participate doi: 10.1007/S00221-021-06244-Z

Not applicable. 11. Batchu S, Diaz MJ, Tran JT, et al. Spatial mapping of genes
implicated in SARS-CoV-2 neuroinvasion to dorsolateral
Consent for publication prefrontal cortex gray matter. COVID. 2023;3(1):82.

Not applicable. doi: 10.3390/COVID3010005
12. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of
Availability of data SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):

Not applicable. 11727-11734.
doi: 10.1073/pnas.2003138117
References
13. Chen YT, Shao SC, Lai ECC, Hung MJ, Chen YC. Mortality
1. COVID-Coronavirus Statistics-Worldometer. Available rate of acute kidney injury in SARS, MERS, and COVID-19
from: https://www.worldometers.info/coronavirus/#google_ infection: A systematic review and meta-analysis. Crit Care.
vignette [Last accessed on 2023 Nove 20]. 2020;24(1):439.
2. Pezzini A, Padovani A. Lifting the mask on neurological doi: 10.1186/S13054-020-03134-8
manifestations of COVID-19. Nat Rev Neurol. 2020;16(11):636- 14. Islam MA, Cavestro C, Alam SS, Kundu S, Kamal MA, Reza F.
644.
Encephalitis in patients with COVID-19: A systematic
doi: 10.1038/s41582-020-0398-3 evidence-based analysis. Cells. 2022;11(16):2575.
3. Dolatshahi M, Sabahi M, Aarabi MH. Pathophysiological doi: 10.3390/CELLS11162575
clues to how the emergent SARS-CoV-2 can potentially 15. Vengalil A, Nizamutdinov D, Su M, Huang JH.
increase the susceptibility to neurodegeneration. Mol Mechanisms of SARS-CoV-2-induced encephalopathy
Neurobiol. 2021;58(5):2379-2394.
and encephalitis in COVID-19 cases. Neurosci Insights.
doi: 10.1007/s12035-020-02236-2 2023;18:26331055231172522.
4. Hu C, Chen C, Dong XP. Impact of COVID-19 pandemic doi: 10.1177/26331055231172522
on patients with neurodegenerative diseases. Front Aging 16. Steardo L, Steardo L, Zorec R, Verkhratsky A.
Neurosci. 2021;13:664965.
Neuroinfection may contribute to pathophysiology and
doi: 10.3389/FNAGI.2021.664965 clinical manifestations of COVID-19. Acta Physiol (Oxf).

Volume 3 Issue 1 (2024) 8 https://doi.org/10.36922/an.2200